A Double Blind, Randomized, Placebo Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy on LDL-C of Evolocumab (AMG 145) in Subjects With HIV and With Hyperlipidemia and/or Mixed Dyslipidemia
Phase of Trial: Phase III
Latest Information Update: 18 Apr 2018
At a glance
- Drugs Evolocumab (Primary)
- Indications Dyslipidaemias; Hyperlipidaemia
- Focus Registrational; Therapeutic Use
- Acronyms BEIJERINCK
- Sponsors Amgen
- 09 Mar 2018 Planned End Date changed from 7 Feb 2020 to 27 Feb 2020.
- 09 Mar 2018 Planned primary completion date changed from 26 Jul 2019 to 15 Aug 2019.
- 10 Jun 2017 Biomarkers information updated